SGCB and stroke disorder: We subjected 8-week-old male and female C57Bl/6 mice to tMCAO and treated with either of two apo-sGC activators, BAY58-2667 or BAY60-2770, at two different doses (30 μg/kg and 10 μg/kg of body weight) respectively, either 1 h or 4 h post-stroke induction.